🔗 Share this article

As the US undertakes sweeping revisions to its immunization recommendations, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by questioning Covid vaccines throughout the global health crisis and has zeroed in on alleged fatalities following COVID-19 immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders planned to announce radical revisions to the childhood immunization program earlier this month, aligning the US with the Danish national calendar, according to reports – a significant shift that would place the US out of step with many the world with no evidence for benefit. The planned update has been pushed back until the next year.

Instead of Vinay Prasad, Høeg is set to present at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth person to lead the office this year.

Consolidating Power at the Regulatory Body

This interim role might represent a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad consolidate power at the agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

Høeg has frequently advocated for ending certain childhood shot schedules in the US to become more in line with Denmark, a country with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccination policy – usually the responsibility of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious track record in medication creation, approval processes or management, which has been customary for former leaders of the CBER. She has worked at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, said Jonathan Howard. “She’s never run a clinical trial. She lacks experience in running a large organization. She has no expertise in industry regulation.”

Former heads of CBER would “understand legal statutes and the science of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she lacks the kind of background that former directors who headed the center have had.”

The drug center has an enormous workload at the agency, Woodcock pointed out.

“Many people just focuses on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those have to be managed,” she noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a significant leadership element to the job, which oversees over 5,000 personnel. “It is a huge leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a representative said that the “inquiries are based on inaccurate presumptions”.

“Her experience matches the functions of her role,” the spokesperson explained, pointing to the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s controversial priority voucher program, a controversial rapid drug-approval program that reportedly worried her former heads. “How are these therapies being chosen for this expedited pathway? Who makes the decisions?” Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Overall, he said, “the FDA looks to be trending towards laxer regulations of all drugs, aside from immunizations.”

Established Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, track record, some experts said. She published a study using unverified volunteer-provided data to assess the rate of myocarditis after COVID-19 vaccination. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the incoming administration encompassed revising guidelines for novel immunizations and halting “non-essential” immunizations, she remarked following the vote on a audio program. At the agency, Høeg has reportedly suggested excluding adolescent males from receiving COVID-19 vaccinations.

“She is an thorough true believer who begins with her conclusions and reverse-engineers to fit the science in a extremely deceptive, dishonest manner,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|